345 related articles for article (PubMed ID: 33090003)
1. Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis.
Samjoo IA; Worthington E; Drudge C; Zhao M; Cameron C; Häring DA; Stoneman D; Klotz L; Adlard N
J Comp Eff Res; 2020 Dec; 9(18):1255-1274. PubMed ID: 33090003
[No Abstract] [Full Text] [Related]
2. Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis.
Samjoo IA; Drudge C; Walsh S; Tiwari S; Brennan R; Boer I; Häring DA; Klotz L; Adlard N; Banhazi J
J Comp Eff Res; 2023 Jul; 12(7):e230016. PubMed ID: 37265062
[No Abstract] [Full Text] [Related]
3. Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
Śladowska K; Kawalec P; Holko P; Osiecka O
Neurol Sci; 2022 Sep; 43(9):5479-5500. PubMed ID: 35713731
[TBL] [Abstract][Full Text] [Related]
4. Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis.
McCool R; Wilson K; Arber M; Fleetwood K; Toupin S; Thom H; Bennett I; Edwards S
Mult Scler Relat Disord; 2019 Apr; 29():55-61. PubMed ID: 30677733
[TBL] [Abstract][Full Text] [Related]
5. Disease modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis.
Liu Z; Liao Q; Wen H; Zhang Y
Autoimmun Rev; 2021 Jun; 20(6):102826. PubMed ID: 33878488
[TBL] [Abstract][Full Text] [Related]
6. Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis.
Samjoo IA; Klotz L; Giovannoni G; Drudge C; Haltner A; Worthington E; Zhao M; Brennan R; Häring DA; Cameron C; Adlard N
Mult Scler Relat Disord; 2022 Oct; 66():104031. PubMed ID: 35841716
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial.
Brittain G; Petrie J; Duffy KEM; Glover R; Hullock K; Papaioannou D; Roldan E; Beecher C; Bursnall M; Ciccarelli O; Coles AJ; Cooper C; Giovannoni G; Gabriel I; Kazmi M; Kyriakou C; Nicholas R; Paling D; Peniket A; Scolding N; Silber E; de Silva T; Venneri A; Walters SJ; Young C; Muraro PA; Sharrack B; Snowden JA;
BMJ Open; 2024 Feb; 14(2):e083582. PubMed ID: 38316583
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis.
Fogarty E; Schmitz S; Tubridy N; Walsh C; Barry M
Mult Scler Relat Disord; 2016 Sep; 9():23-30. PubMed ID: 27645339
[TBL] [Abstract][Full Text] [Related]
9. Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches.
Berardi A; Siddiqui MK; Treharne C; Harty G; Wong SL
Curr Med Res Opin; 2019 Aug; 35(8):1371-1378. PubMed ID: 30786783
[No Abstract] [Full Text] [Related]
10. Letter to the Editor: comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis.
Parekh K; Watkins C
J Comp Eff Res; 2021 Dec; 10(17):1265-1266. PubMed ID: 34608807
[No Abstract] [Full Text] [Related]
11. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
Li H; Hu F; Zhang Y; Li K
J Neurol; 2020 Dec; 267(12):3489-3498. PubMed ID: 31129710
[TBL] [Abstract][Full Text] [Related]
12. Efficacy classification of modern therapies in multiple sclerosis.
Samjoo IA; Worthington E; Drudge C; Zhao M; Cameron C; Häring DA; Stoneman D; Klotz L; Adlard N
J Comp Eff Res; 2021 Apr; 10(6):495-507. PubMed ID: 33620251
[No Abstract] [Full Text] [Related]
13. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis.
Siddiqui MK; Khurana IS; Budhia S; Hettle R; Harty G; Wong SL
Curr Med Res Opin; 2018 Aug; 34(8):1361-1371. PubMed ID: 29149804
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy of ofatumumab
Riley N; Drudge C; Nelson M; Haltner A; Barnett M; Broadley S; Butzkueven H; McCombe P; Van der Walt A; Wong EOY; Merschhemke M; Adlard N; Walker R; Samjoo IA
Ther Adv Neurol Disord; 2024; 17():17562864241239453. PubMed ID: 38525490
[TBL] [Abstract][Full Text] [Related]
15. Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis.
Lucchetta RC; Tonin FS; Borba HHL; Leonart LP; Ferreira VL; Bonetti AF; Riveros BS; Becker J; Pontarolo R; Fernandez-Llimós F; Wiens A
CNS Drugs; 2018 Sep; 32(9):813-826. PubMed ID: 30014314
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy and safety of disease-modifying therapies in patients with relapsing multiple sclerosis: A systematic review and network meta-analysis.
Chen C; Zhang E; Zhu C; Wei R; Ma L; Dong X; Li R; Sun F; Zhou Y; Cui Y; Liu Z
J Am Pharm Assoc (2003); 2023; 63(1):8-22.e23. PubMed ID: 36055929
[TBL] [Abstract][Full Text] [Related]
18. Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis.
Kang C; Blair HA
Drugs; 2022 Jan; 82(1):55-62. PubMed ID: 34897575
[TBL] [Abstract][Full Text] [Related]
19. Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL; Bar-Or A; Cohen JA; Comi G; Correale J; Coyle PK; Cross AH; de Seze J; Leppert D; Montalban X; Selmaj K; Wiendl H; Kerloeguen C; Willi R; Li B; Kakarieka A; Tomic D; Goodyear A; Pingili R; Häring DA; Ramanathan K; Merschhemke M; Kappos L;
N Engl J Med; 2020 Aug; 383(6):546-557. PubMed ID: 32757523
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
Hutchinson M; Fox RJ; Havrdova E; Kurukulasuriya NC; Sarda SP; Agarwal S; Siddiqui MK; Taneja A; Deniz B
Curr Med Res Opin; 2014 Apr; 30(4):613-27. PubMed ID: 24195574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]